Results 191 to 200 of about 378,540 (249)
Some of the next articles are maybe not open access.
Zeitschrift für Rheumatologie, 2006
Juvenile dermatomyositis (JDM) is an inflammatory multi-system disease of unknown etiology with classic involvement of the skin and striated muscles. Following a prodromal period, patients develop a progressive proximal muscle weakness. Typical skin involvement includes heliotrope rash, facial erythema, Gottron's sign and nailfold capillary ...
F, Dressler, H-I, Huppertz
openaire +2 more sources
Juvenile dermatomyositis (JDM) is an inflammatory multi-system disease of unknown etiology with classic involvement of the skin and striated muscles. Following a prodromal period, patients develop a progressive proximal muscle weakness. Typical skin involvement includes heliotrope rash, facial erythema, Gottron's sign and nailfold capillary ...
F, Dressler, H-I, Huppertz
openaire +2 more sources
2013
Juvenile dermatomyositis (JDM) is a systemic, inflammatory, idiopathic disease, mainly affecting the skin and the muscles, starting before the age of 16, with an incidence around one case per 1 million children. Some patients display typical features of JDM without skin involvement, or even without muscle involvement; however, both tissues are affected
Pierre, Quartier, Romain K, Gherardi
openaire +2 more sources
Juvenile dermatomyositis (JDM) is a systemic, inflammatory, idiopathic disease, mainly affecting the skin and the muscles, starting before the age of 16, with an incidence around one case per 1 million children. Some patients display typical features of JDM without skin involvement, or even without muscle involvement; however, both tissues are affected
Pierre, Quartier, Romain K, Gherardi
openaire +2 more sources
Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Current pediatric reviews, 2021BACKGROUND Juvenile dermatomyositis is the most common inflammatory myopathy in the pediatric age group and a major cause of mortality and morbidity in individuals with childhood rheumatic diseases.
A. Leung +4 more
semanticscholar +1 more source
Autologous CD19‐Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis
Arthritis & RheumatologyThe aim of this study is to report the safety and efficacy of CD19‐targeting chimeric antigen receptor (CAR) T cells in a child with refractory juvenile dermatomyositis (JDM).
R. Nicolai +15 more
semanticscholar +1 more source
Rheumatic Disease Clinics of North America, 1991
Juvenile dermatomyositis is a relatively rare, multisystem disease characterized by a nonsuppurative myositis which causes symmetrical weakness, rash and vasculitis; this last can affect the gastrointestinal tract and the myocardium. Late development of calcinosis is seen in approximately two thirds of patients.
openaire +3 more sources
Juvenile dermatomyositis is a relatively rare, multisystem disease characterized by a nonsuppurative myositis which causes symmetrical weakness, rash and vasculitis; this last can affect the gastrointestinal tract and the myocardium. Late development of calcinosis is seen in approximately two thirds of patients.
openaire +3 more sources
Pediatrics
This report outlines the case of a 9-year-old girl with severe anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis presenting with disease refractory to multiple traditional therapies.
Justina Guirguis +6 more
semanticscholar +1 more source
This report outlines the case of a 9-year-old girl with severe anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis presenting with disease refractory to multiple traditional therapies.
Justina Guirguis +6 more
semanticscholar +1 more source
Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Seminars in Arthritis & RheumatismBACKGROUND/OBJECTIVES Janus kinase (JAK) inhibitors have been increasingly used in the treatment of juvenile dermatomyositis (JDM). This review aims to comprehensively analyze previous studies concerning the utilization of JAK inhibitors in JDM patients.
S. Şener +3 more
semanticscholar +1 more source
Expert Opinion on Pharmacotherapy
Introduction Adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) are rare autoimmune diseases with characteristic skin rashes, weakness, and other systemic features. Upregulated interferon signaling has been consistently described in both adult
R. Wallwork, Julie J. Paik, Hanna Kim
semanticscholar +1 more source
Introduction Adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) are rare autoimmune diseases with characteristic skin rashes, weakness, and other systemic features. Upregulated interferon signaling has been consistently described in both adult
R. Wallwork, Julie J. Paik, Hanna Kim
semanticscholar +1 more source
International Journal of Rheumatic Diseases, 2021
Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely
Poh Lin Pauline Chan Ng +7 more
semanticscholar +1 more source
Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely
Poh Lin Pauline Chan Ng +7 more
semanticscholar +1 more source
Angiokeratomas in Juvenile Dermatomyositis
Pediatric Dermatology, 1999Abstract: Juvenile dermatomyositis (JDM) is an uncommon disease that features muscle weakness, a characteristic rash, and vascular changes in skin, muscle, and other organs. We report a patient with JDM who developed multiple angiokeratomas, one of which was calcified.
P L, Shannon, M J, Ford
openaire +2 more sources